Maravai LifeSciences operates two business segments serving the biopharmaceutical, vaccine, and research communities. TriLink manufactures and sells highly modified nucleic acids and protein labeling and detection products supporting customer research, therapeutic development, and vaccine programs. Cygnus manufactures diagnostic kits and provides specialized services for bioprocess quality control, including host cell protein detection, viral clearance prediction, custom antibody development, assay development, and mass spectrometry analysis used in biologic drug manufacturing. The company generates revenue through product sales and specialized services that provide essential tools to customers engaged in therapeutic development and manufacturing.